Jobs / United States / Glaxosmithkline LLC
AI Transformation & Enablement Director
Glaxosmithkline LLC · 🇺🇸 4 Locations
Sponsorship verdict
Sponsorship possible
One solid signal, not two — worth applying, and worth asking about sponsorship early.
- Employer is on a government sponsor recordThe US Department of Labor certified 39 H-1B/E-3 labor condition applications for this employer between Oct 2025 and Jun 2026 (latest Jun 2026) — the step every H-1B hire needs first. USCIS also records 15 H-1B approvals in FY2023. Source: LCA disclosure data (US Department of Labor (OFLC)).
- The posting doesn’t mention sponsorshipSilence isn’t a refusal — ask the recruiter before investing much time.
- No salary bar for this routeH-1B has no fixed salary bar: the employer must pay at least the prevailing wage for the role and area. Cap-subject employers enter a lottery weighted by wage level. Source: https://www.federalregister.gov/documents/2025/12/29/2025-23853/weighted-selection-process-for-registrants-and-petitioners-seeking-to-file-cap-subject-h-1b, rules effective 2026-02-27.
- What Glaxosmithkline LLC paid sponsored hires in similar roles4 certified filings for “Associate Director – Genomic Technologies” (Molecular and Cellular Biologists) in PA: $134k–$138k, median $136k. Most were filed at wage level IV (50%) — 4 lottery entries, ≈61% projected selection odds for cap-subject employers. Source: US Department of Labor LCA disclosure data (Oct 2025 – Jun 2026).
- Confirmed live todayWhen a source last listed this job as open.
US H-1B: cap-subject employers enter a lottery weighted by wage level — Level I gets 1 entry, Level IV gets 4 (DHS projected selection odds ≈15% at Level I to ≈61% at Level IV). Universities and non-profit research employers are cap-exempt. The $100,000 fee for new petitions from abroad is currently blocked by a court order (appeal pending).
A verdict summarises public evidence; it is not legal advice and never a guarantee — the employer and the immigration authority decide. Sign in to factor in where you can already work.
Or apply yourself on the official page →
Sponsor Radar — Glaxosmithkline LLC
The US Department of Labor certified 39 H-1B/E-3 labor condition applications for this employer between Oct 2025 and Jun 2026 (latest Jun 2026) — the step every H-1B hire needs first. USCIS also records 15 H-1B approvals in FY2023. Source: LCA disclosure data (US Department of Labor (OFLC)).
Past sponsorship or register membership never guarantees sponsorship for this vacancy or for you. Full Sponsor Radar for Glaxosmithkline LLC →
About the role
AI Transformation and Enablement Director, Development Global Clinical Operations This role sits within DP&I (Development Operations Platforms & Innovation), part of Development Global Clinical Operations at GSK. DP&I is building the capability to deploy AI at scale across clinical operations and the wider Development Operations function, with a mandate to help reshape how GSK plans, delivers, and continuously improves clinical trials. DP&I develops and deploys scalable, AI-native capabilities, shared foundations, and new ways of working across Development Operations. Working across clinical operations, technology, product, data, and external partners, the team builds the platforms, products, and partnerships needed to turn innovation into measurable value. Job Purpose As AI Transformation and Enablement Director, you will drive how agentic AI becomes the way all people across Development Operations deliver high quality work, and you will own what that means for how the function works. You will define the strategy and its multi-year roadmap, and build and defend the investment behind it. You will own what adoption, and exponentially increasing machine capability, mean for how work evolves across Development Operations and for the operating model: where work sits, which roles change, and which processes get fundamentally reinvented rather than automated as they stand. You will set the bar on what gets taken from ground-up build into production, and hold the view on which agentic tooling the function should be using, from the frontier labs through to open-weight and locally run models. You will be Development Operations' voice into the R&D-wide and enterprise agentic AI agenda. This role reports into the Head of Asset Acceleration and AI. You will shape how GSK uses AI to measurably improve clinical development delivery and improve outcomes for patients. Key Responsibilities Strategy, roadmap and investment • Drive the agentic AI transformation and enablement strategy for Development Operations, its multi-year roadmap and the prioritisation across it, anchored to measurable clinical trial outcomes. • Build and defend the investment case for transformation at scale, with clear ROI and payback logic, and enforce stage-gate discipline, including the call to stop or reshape what does not demonstrate value. How the work itself changes • Own what widespread agentic adoption and exponentially increasing machine capability mean for how Development Operations is organised: where work sits, which roles change, and how the function operates. • Define which processes get fundamentally reinvented rather than automated as they stand. • Carry those changes with functional leaders as their peer, so that adoption changes how the work is actually done. Agentic tooling across Development Operations • Hold the view on which agentic tooling Development Operations should be using, across frontier labs, open-weight and locally run models, judged on adoption, enablement, cost, output quality and compliant deployment. • Keep that view current against a fast-moving landscape, and influence central decision making so that Development Operations ends up with appropriate, effective usage, with the evidence and the experiments behind it. Capability and adoption at scale • Make frontier agentic tools routine practice across every group, and set the direction for the learning and capability teams and the Champion Network that deliver it. • Hold the function accountable for adoption: who is using what, how deeply, where uptake has stalled, and what changes as a result. • Set the quality bar for ground-up build, and decide what gets productionised and what stays as local self-serve tooling. Enterprise alignment and delivery • Act as Development O